カテゴリー： QYResearch, 世界, 医療/バイオ

世界のウイルス＆非ウイルスベクター製造市場インサイト及び予測（ウィルス性ベクター、非ウィルス性ベクター）

◆英語タイトル：Global Viral and Non-Viral Vector Manufacturing Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JLX09304）◆商品コード：QY22JLX09304
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：125
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、ウイルス＆非ウイルスベクター製造のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にウイルス＆非ウイルスベクター製造の世界市場のxxx％を占める「ウィルス性ベクター」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「遺伝子治療」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
ウイルス＆非ウイルスベクター製造の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのウイルス＆非ウイルスベクター製造市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

ウイルス＆非ウイルスベクター製造のグローバル主要企業には、Boehringer Ingelheim、Catalent, Inc.、FUJIFILM Holdings Corporation、Danaher Corporation、Genscript Biotech Corporation、Lonza Group AG、Merck KGaA Inc.、Oxford Biomedica Plc、Sartorius AG、Takara Bio Inc.、Thermo Fisher Scientific Inc.、Wuxi AppTec、Acuitas Therapeutics、Evonik Industries AG、Exelead, Inc.、Entos Pharmaceuticals、Genevant Sciences GmbH、T&T Scientific Corporation、Moderna, Inc.、CureVac N.V.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

ウイルス＆非ウイルスベクター製造市場は、種類と用途によって区分されます。世界のウイルス＆非ウイルスベクター製造市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ウィルス性ベクター、非ウィルス性ベクター

【用途別セグメント】
遺伝子治療、ワクチン、細胞治療、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- ウイルス＆非ウイルスベクター製造製品概要
- 種類別市場（ウィルス性ベクター、非ウィルス性ベクター）
- 用途別市場（遺伝子治療、ワクチン、細胞治療、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のウイルス＆非ウイルスベクター製造販売量予測2017-2028
- 世界のウイルス＆非ウイルスベクター製造売上予測2017-2028
- ウイルス＆非ウイルスベクター製造の地域別販売量
- ウイルス＆非ウイルスベクター製造の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ウイルス＆非ウイルスベクター製造販売量
- 主要メーカー別ウイルス＆非ウイルスベクター製造売上
- 主要メーカー別ウイルス＆非ウイルスベクター製造価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ウィルス性ベクター、非ウィルス性ベクター）
- ウイルス＆非ウイルスベクター製造の種類別販売量
- ウイルス＆非ウイルスベクター製造の種類別売上
- ウイルス＆非ウイルスベクター製造の種類別価格
・用途別市場規模（遺伝子治療、ワクチン、細胞治療、その他）
- ウイルス＆非ウイルスベクター製造の用途別販売量
- ウイルス＆非ウイルスベクター製造の用途別売上
- ウイルス＆非ウイルスベクター製造の用途別価格
・北米市場
- 北米のウイルス＆非ウイルスベクター製造市場規模（種類別、用途別）
- 主要国別のウイルス＆非ウイルスベクター製造市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのウイルス＆非ウイルスベクター製造市場規模（種類別、用途別）
- 主要国別のウイルス＆非ウイルスベクター製造市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のウイルス＆非ウイルスベクター製造市場規模（種類別、用途別）
- 主要国別のウイルス＆非ウイルスベクター製造市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のウイルス＆非ウイルスベクター製造市場規模（種類別、用途別）
- 主要国別のウイルス＆非ウイルスベクター製造市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのウイルス＆非ウイルスベクター製造市場規模（種類別、用途別）
- 主要国別のウイルス＆非ウイルスベクター製造市場規模（トルコ、サウジアラビア）
・企業情報
Boehringer Ingelheim、Catalent, Inc.、FUJIFILM Holdings Corporation、Danaher Corporation、Genscript Biotech Corporation、Lonza Group AG、Merck KGaA Inc.、Oxford Biomedica Plc、Sartorius AG、Takara Bio Inc.、Thermo Fisher Scientific Inc.、Wuxi AppTec、Acuitas Therapeutics、Evonik Industries AG、Exelead, Inc.、Entos Pharmaceuticals、Genevant Sciences GmbH、T&T Scientific Corporation、Moderna, Inc.、CureVac N.V.
・産業チェーン及び販売チャネル分析
- ウイルス＆非ウイルスベクター製造の産業チェーン分析
- ウイルス＆非ウイルスベクター製造の原材料
- ウイルス＆非ウイルスベクター製造の生産プロセス
- ウイルス＆非ウイルスベクター製造の販売及びマーケティング
- ウイルス＆非ウイルスベクター製造の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ウイルス＆非ウイルスベクター製造の産業動向
- ウイルス＆非ウイルスベクター製造のマーケットドライバー
- ウイルス＆非ウイルスベクター製造の課題
- ウイルス＆非ウイルスベクター製造の阻害要因
・主な調査結果

Market Analysis and Insights: Global Viral and Non-Viral Vector Manufacturing Market
The global Viral and Non-Viral Vector Manufacturing market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Viral Vectors accounting for % of the Viral and Non-Viral Vector Manufacturing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Gene Therapy segment is altered to an % CAGR throughout this forecast period.
China Viral and Non-Viral Vector Manufacturing market size is valued at US$ million in 2021, while the North America and Europe Viral and Non-Viral Vector Manufacturing are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Viral and Non-Viral Vector Manufacturing landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Viral and Non-Viral Vector Manufacturing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Viral and Non-Viral Vector Manufacturing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Viral and Non-Viral Vector Manufacturing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Viral and Non-Viral Vector Manufacturing market.
Global Viral and Non-Viral Vector Manufacturing Scope and Market Size
Viral and Non-Viral Vector Manufacturing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Viral and Non-Viral Vector Manufacturing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Viral Vectors
Non-Viral Vectors
Segment by Application
Gene Therapy
Vaccinology
Cell Therapy
Others
By Company
Boehringer Ingelheim
Catalent, Inc.
FUJIFILM Holdings Corporation
Danaher Corporation
Genscript Biotech Corporation
Lonza Group AG
Merck KGaA Inc.
Oxford Biomedica Plc
Sartorius AG
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Wuxi AppTec
Acuitas Therapeutics
Evonik Industries AG
Exelead, Inc.
Entos Pharmaceuticals
Genevant Sciences GmbH
T&T Scientific Corporation
Moderna, Inc.
CureVac N.V.
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral and Non-Viral Vector Manufacturing Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Viral Vectors
1.2.3 Non-Viral Vectors
1.3 Market by Application
1.3.1 Global Viral and Non-Viral Vector Manufacturing Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Gene Therapy
1.3.3 Vaccinology
1.3.4 Cell Therapy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Viral and Non-Viral Vector Manufacturing Market Perspective (2017-2028)
2.2 Viral and Non-Viral Vector Manufacturing Growth Trends by Region
2.2.1 Viral and Non-Viral Vector Manufacturing Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Viral and Non-Viral Vector Manufacturing Historic Market Size by Region (2017-2022)
2.2.3 Viral and Non-Viral Vector Manufacturing Forecasted Market Size by Region (2023-2028)
2.3 Viral and Non-Viral Vector Manufacturing Market Dynamics
2.3.1 Viral and Non-Viral Vector Manufacturing Industry Trends
2.3.2 Viral and Non-Viral Vector Manufacturing Market Drivers
2.3.3 Viral and Non-Viral Vector Manufacturing Market Challenges
2.3.4 Viral and Non-Viral Vector Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral and Non-Viral Vector Manufacturing Players by Revenue
3.1.1 Global Top Viral and Non-Viral Vector Manufacturing Players by Revenue (2017-2022)
3.1.2 Global Viral and Non-Viral Vector Manufacturing Revenue Market Share by Players (2017-2022)
3.2 Global Viral and Non-Viral Vector Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Viral and Non-Viral Vector Manufacturing Revenue
3.4 Global Viral and Non-Viral Vector Manufacturing Market Concentration Ratio
3.4.1 Global Viral and Non-Viral Vector Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral and Non-Viral Vector Manufacturing Revenue in 2021
3.5 Viral and Non-Viral Vector Manufacturing Key Players Head office and Area Served
3.6 Key Players Viral and Non-Viral Vector Manufacturing Product Solution and Service
3.7 Date of Enter into Viral and Non-Viral Vector Manufacturing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral and Non-Viral Vector Manufacturing Breakdown Data by Type
4.1 Global Viral and Non-Viral Vector Manufacturing Historic Market Size by Type (2017-2022)
4.2 Global Viral and Non-Viral Vector Manufacturing Forecasted Market Size by Type (2023-2028)
5 Viral and Non-Viral Vector Manufacturing Breakdown Data by Application
5.1 Global Viral and Non-Viral Vector Manufacturing Historic Market Size by Application (2017-2022)
5.2 Global Viral and Non-Viral Vector Manufacturing Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Viral and Non-Viral Vector Manufacturing Market Size (2017-2028)
6.2 North America Viral and Non-Viral Vector Manufacturing Market Size by Type
6.2.1 North America Viral and Non-Viral Vector Manufacturing Market Size by Type (2017-2022)
6.2.2 North America Viral and Non-Viral Vector Manufacturing Market Size by Type (2023-2028)
6.2.3 North America Viral and Non-Viral Vector Manufacturing Market Share by Type (2017-2028)
6.3 North America Viral and Non-Viral Vector Manufacturing Market Size by Application
6.3.1 North America Viral and Non-Viral Vector Manufacturing Market Size by Application (2017-2022)
6.3.2 North America Viral and Non-Viral Vector Manufacturing Market Size by Application (2023-2028)
6.3.3 North America Viral and Non-Viral Vector Manufacturing Market Share by Application (2017-2028)
6.4 North America Viral and Non-Viral Vector Manufacturing Market Size by Country
6.4.1 North America Viral and Non-Viral Vector Manufacturing Market Size by Country (2017-2022)
6.4.2 North America Viral and Non-Viral Vector Manufacturing Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Viral and Non-Viral Vector Manufacturing Market Size (2017-2028)
7.2 Europe Viral and Non-Viral Vector Manufacturing Market Size by Type
7.2.1 Europe Viral and Non-Viral Vector Manufacturing Market Size by Type (2017-2022)
7.2.2 Europe Viral and Non-Viral Vector Manufacturing Market Size by Type (2023-2028)
7.2.3 Europe Viral and Non-Viral Vector Manufacturing Market Share by Type (2017-2028)
7.3 Europe Viral and Non-Viral Vector Manufacturing Market Size by Application
7.3.1 Europe Viral and Non-Viral Vector Manufacturing Market Size by Application (2017-2022)
7.3.2 Europe Viral and Non-Viral Vector Manufacturing Market Size by Application (2023-2028)
7.3.3 Europe Viral and Non-Viral Vector Manufacturing Market Share by Application (2017-2028)
7.4 Europe Viral and Non-Viral Vector Manufacturing Market Size by Country
7.4.1 Europe Viral and Non-Viral Vector Manufacturing Market Size by Country (2017-2022)
7.4.2 Europe Viral and Non-Viral Vector Manufacturing Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size (2017-2028)
8.2 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Type
8.2.1 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Share by Type (2017-2028)
8.3 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Application
8.3.1 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Share by Application (2017-2028)
8.4 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Region
8.4.1 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Viral and Non-Viral Vector Manufacturing Market Size (2017-2028)
9.2 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Type
9.2.1 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Type (2017-2022)
9.2.2 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Type (2023-2028)
9.2.3 Latin America Viral and Non-Viral Vector Manufacturing Market Share by Type (2017-2028)
9.3 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Application
9.3.1 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Application (2017-2022)
9.3.2 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Application (2023-2028)
9.3.3 Latin America Viral and Non-Viral Vector Manufacturing Market Share by Application (2017-2028)
9.4 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Country
9.4.1 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Country (2017-2022)
9.4.2 Latin America Viral and Non-Viral Vector Manufacturing Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size (2017-2028)
10.2 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Type
10.2.1 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Share by Type (2017-2028)
10.3 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Application
10.3.1 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Share by Application (2017-2028)
10.4 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Country
10.4.1 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Viral and Non-Viral Vector Manufacturing Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Details
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Viral and Non-Viral Vector Manufacturing Introduction
11.1.4 Boehringer Ingelheim Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Catalent, Inc.
11.2.1 Catalent, Inc. Company Details
11.2.2 Catalent, Inc. Business Overview
11.2.3 Catalent, Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.2.4 Catalent, Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.2.5 Catalent, Inc. Recent Developments
11.3 FUJIFILM Holdings Corporation
11.3.1 FUJIFILM Holdings Corporation Company Details
11.3.2 FUJIFILM Holdings Corporation Business Overview
11.3.3 FUJIFILM Holdings Corporation Viral and Non-Viral Vector Manufacturing Introduction
11.3.4 FUJIFILM Holdings Corporation Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.3.5 FUJIFILM Holdings Corporation Recent Developments
11.4 Danaher Corporation
11.4.1 Danaher Corporation Company Details
11.4.2 Danaher Corporation Business Overview
11.4.3 Danaher Corporation Viral and Non-Viral Vector Manufacturing Introduction
11.4.4 Danaher Corporation Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.4.5 Danaher Corporation Recent Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Details
11.5.2 Genscript Biotech Corporation Business Overview
11.5.3 Genscript Biotech Corporation Viral and Non-Viral Vector Manufacturing Introduction
11.5.4 Genscript Biotech Corporation Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.5.5 Genscript Biotech Corporation Recent Developments
11.6 Lonza Group AG
11.6.1 Lonza Group AG Company Details
11.6.2 Lonza Group AG Business Overview
11.6.3 Lonza Group AG Viral and Non-Viral Vector Manufacturing Introduction
11.6.4 Lonza Group AG Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.6.5 Lonza Group AG Recent Developments
11.7 Merck KGaA Inc.
11.7.1 Merck KGaA Inc. Company Details
11.7.2 Merck KGaA Inc. Business Overview
11.7.3 Merck KGaA Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.7.4 Merck KGaA Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.7.5 Merck KGaA Inc. Recent Developments
11.8 Oxford Biomedica Plc
11.8.1 Oxford Biomedica Plc Company Details
11.8.2 Oxford Biomedica Plc Business Overview
11.8.3 Oxford Biomedica Plc Viral and Non-Viral Vector Manufacturing Introduction
11.8.4 Oxford Biomedica Plc Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.8.5 Oxford Biomedica Plc Recent Developments
11.9 Sartorius AG
11.9.1 Sartorius AG Company Details
11.9.2 Sartorius AG Business Overview
11.9.3 Sartorius AG Viral and Non-Viral Vector Manufacturing Introduction
11.9.4 Sartorius AG Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.9.5 Sartorius AG Recent Developments
11.10 Takara Bio Inc.
11.10.1 Takara Bio Inc. Company Details
11.10.2 Takara Bio Inc. Business Overview
11.10.3 Takara Bio Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.10.4 Takara Bio Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.10.5 Takara Bio Inc. Recent Developments
11.11 Thermo Fisher Scientific Inc.
11.11.1 Thermo Fisher Scientific Inc. Company Details
11.11.2 Thermo Fisher Scientific Inc. Business Overview
11.11.3 Thermo Fisher Scientific Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.11.4 Thermo Fisher Scientific Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.11.5 Thermo Fisher Scientific Inc. Recent Developments
11.12 Wuxi AppTec
11.12.1 Wuxi AppTec Company Details
11.12.2 Wuxi AppTec Business Overview
11.12.3 Wuxi AppTec Viral and Non-Viral Vector Manufacturing Introduction
11.12.4 Wuxi AppTec Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.12.5 Wuxi AppTec Recent Developments
11.13 Acuitas Therapeutics
11.13.1 Acuitas Therapeutics Company Details
11.13.2 Acuitas Therapeutics Business Overview
11.13.3 Acuitas Therapeutics Viral and Non-Viral Vector Manufacturing Introduction
11.13.4 Acuitas Therapeutics Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.13.5 Acuitas Therapeutics Recent Developments
11.14 Evonik Industries AG
11.14.1 Evonik Industries AG Company Details
11.14.2 Evonik Industries AG Business Overview
11.14.3 Evonik Industries AG Viral and Non-Viral Vector Manufacturing Introduction
11.14.4 Evonik Industries AG Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.14.5 Evonik Industries AG Recent Developments
11.15 Exelead, Inc.
11.15.1 Exelead, Inc. Company Details
11.15.2 Exelead, Inc. Business Overview
11.15.3 Exelead, Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.15.4 Exelead, Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.15.5 Exelead, Inc. Recent Developments
11.16 Entos Pharmaceuticals
11.16.1 Entos Pharmaceuticals Company Details
11.16.2 Entos Pharmaceuticals Business Overview
11.16.3 Entos Pharmaceuticals Viral and Non-Viral Vector Manufacturing Introduction
11.16.4 Entos Pharmaceuticals Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.16.5 Entos Pharmaceuticals Recent Developments
11.17 Genevant Sciences GmbH
11.17.1 Genevant Sciences GmbH Company Details
11.17.2 Genevant Sciences GmbH Business Overview
11.17.3 Genevant Sciences GmbH Viral and Non-Viral Vector Manufacturing Introduction
11.17.4 Genevant Sciences GmbH Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.17.5 Genevant Sciences GmbH Recent Developments
11.18 T&T Scientific Corporation
11.18.1 T&T Scientific Corporation Company Details
11.18.2 T&T Scientific Corporation Business Overview
11.18.3 T&T Scientific Corporation Viral and Non-Viral Vector Manufacturing Introduction
11.18.4 T&T Scientific Corporation Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.18.5 T&T Scientific Corporation Recent Developments
11.19 Moderna, Inc.
11.19.1 Moderna, Inc. Company Details
11.19.2 Moderna, Inc. Business Overview
11.19.3 Moderna, Inc. Viral and Non-Viral Vector Manufacturing Introduction
11.19.4 Moderna, Inc. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.19.5 Moderna, Inc. Recent Developments
11.20 CureVac N.V.
11.20.1 CureVac N.V. Company Details
11.20.2 CureVac N.V. Business Overview
11.20.3 CureVac N.V. Viral and Non-Viral Vector Manufacturing Introduction
11.20.4 CureVac N.V. Revenue in Viral and Non-Viral Vector Manufacturing Business (2017-2022)
11.20.5 CureVac N.V. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のウイルス＆非ウイルスベクター製造市場インサイト及び予測（ウィルス性ベクター、非ウィルス性ベクター）(Global Viral and Non-Viral Vector Manufacturing Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • カスタムベクターサービスのグローバル市場展望 2023年-2029年：ウイルスベクター、プラスミドベクター、RNAベクター
  • ウイルスDNA精製キットのグローバル市場2023年：48回分、50回分、その他
  • 世界のバクテリアウイルスフィルター（BVF）市場インサイト及び予測（22mm、30mm、その他）
  • 世界のUTMウイルス輸送市場インサイト及び予測（1.0ML、3.0ML、その他）
  • 世界のウイルスワクチン細胞培養培地市場インサイト及び予測（付着性、懸濁性）